Bowel cancer incidence statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Cases

New cases of bowel cancer, 2015-2017, UK.

 

Proportion of all cases

Percentage bowel cancer is of total cancer cases, 2015-2017, UK

 

Age

Peak rate of bowel cancer cases, 2015-2017, UK

 

Trend over time

Bowel cancer incidence rates have changed differently for each sex since the early 1990s, UK

 

Bowel cancer is the 4th most common cancer in the UK, accounting for 11% of all new cancer cases (2017).[1-4]

In females in the UK, bowel cancer is the 3rd most common cancer (10% of all new female cancer cases). In males in the UK, it is the 3rd most common cancer (13% of all new male cancer cases).

44% of bowel cancer cases in the UK are in females, and 56% are in males.

Bowel cancer incidence rates (European age-standardised (AS) rates) Open a glossary item for persons are significantly higher than the UK average in Scotland and Wales, and similar to the UK average in all other UK constituent countries.

Bowel Cancer (C18-C20), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Cases 15,410 1,632 994 529 18,565
Crude Rate 54.8 58.6 62.7 55.6 55.5
AS Rate 54.9 56.3 56.9 60.4 55.2
AS Rate - 95% LCL 54.0 53.6 53.4 55.3 54.5
AS Rate - 95% UCL 55.7 59.0 60.5 65.6 56.0
Male Cases 19,415 2,154 1,321 626 23,516
Crude Rate 70.6 81.6 85.8 68.0 72.2
AS Rate 81.9 91.4 89.5 86.2 83.2
AS Rate - 95% LCL 80.8 87.5 84.7 79.4 82.2
AS Rate - 95% UCL 83.1 95.2 94.3 92.9 84.3
Persons Cases 34,825 3,786 2,315 1,155 42,081
Crude Rate 62.6 69.8 74.1 61.7 63.7
AS Rate 67.3 71.8 71.8 71.8 68.0
AS Rate - 95% LCL 66.6 69.5 68.9 67.7 67.4
AS Rate - 95% UCL 68.0 74.1 74.7 75.9 68.7

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item  around the AS Rate  Open a glossary item
 

For bowel cancer, like most cancer types, differences between countries largely reflect risk factor prevalence in years past.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 C18-C20.

Last reviewed:

Bowel cancer incidence is strongly related to age, with the highest incidence rates being in older people. In the UK in 2015-2017, on average each year more than 4 in 10 new cases (44%) were in people aged 75 and over.[1-4]

Age-specific incidence rates rise steeply from around age 50-54. The highest rates are in the 85 to 89 age group for females and males.

Incidence rates are significantly lower in females than males in a number of (mainly older) age groups. The gap is widest at age 65 to 69, when the age-specific incidence rate is 1.7 times lower in females than males.

Bowel cancer (C18-C20), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2015-2017

For bowel cancer, like most cancer types, incidence increases with age. The impact of routine screening on the age profile of bowel cancer is hard to discern, as bowel screening aims both to prevent and to diagnose early; these effects on the incidence trend may cancel one another out.

The overall increase in incidence with age largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, C18-C20.

Last reviewed:

Bowel cancer European age-standardised (AS) Open a glossary item incidence rates for females and males combined remained stable in the UK between 1993-1995 and 2015-2017.[1-4] The change varied markedly between sexes.

For females, bowel cancer AS incidence rates in the UK remained stable between 1993-1995 and 2015-2017. For males, bowel cancer AS incidence rates in the UK decreased by 3% between 1993-1995 and 2015-2017.

Over the last decade in the UK (between 2005-2007 and 2015-2017), bowel cancer AS incidence rates for females and males combined decreased by 4%. In females AS incidence rates decreased by 2%, and in males rates decreased by 6%.

Bowel Cancer (ICD-10 C18-C20), European Age-Standardised Incidence Rates, UK, 1993-2017

Bowel Cancer incidence rates have remained stable overall in some broad adult age groups, in females and males combined in the UK since the early 1990s but have increased or decreased in others.[1-4] Rates in 25-49s have increased by 41%, in 50-59s have remained stable, in 60-74s have decreased by 6%, in 75-79s have remained stable, and in 80+s have remained stable.     

Bowel Cancer (ICD-10 C18-C20), European Age-Standardised Incidence Rates, By Age, UK, 1993-2017

For bowel cancer, like most cancer types, incidence trends largely reflect changing prevalence of risk factors and improvements in diagnosis and data recording. Recent incidence trends are influenced by risk factor prevalence in years past, and trends by age group reflect risk factor exposure in birth cohorts.

The introduction of the bowel screening programmes in the mid-2000s probably also plays a part.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/

About this data

Data is for UK, 1993-2017, ICD-10 C18-C20.

Last reviewed:

Overall stage at diagnosis

A high proportion (87-90%) of bowel cancer cases in England, Scotland and Northern Ireland have stage at diagnosis recorded.[1-3]

More bowel cancer patients with a known stage are diagnosed at a late stage (52-56% are diagnosed at stage III or IV), than an early stage (44-48% are diagnosed at stage I or II). Around 23-26% of bowel cancer patients have metastases at diagnosis (stage IV).[1-3]

The stage distribution for each cancer type will reflect many factors including how the cancer type develops, the way symptoms appear, public awareness of symptoms, how quickly a person goes to see their doctor and how quickly the cancer is recognised and diagnosed by a doctor. It might also relate to whether a national screening programme that can detect early stage disease exists for that cancer type, along with the extent of uptake of that programme.

A cancer type associated with a large proportion of early stage diagnoses could be one that is more likely to be symptomatic at an earlier stage of development, with recognisable symptoms rather than more generic ones.

Bowel Cancer (C18-C20), Proportion of Cases Diagnosed at Each Stage, All Ages, England 2014, Scotland 2014-15, and Northern Ireland 2010-2014

Data should not be compared between countries due to differences in time periods and possible differences in recording of stage at diagnosis.

Stage at diagnosis by deprivation

Late stage at diagnosis of bowel cancer in England is associated with higher deprivation. Among adults aged 15-99 in England, 57% of those in the most deprived areas are diagnosed at stage III or IV, versus 54% of those in the least deprived areas.[4]

Stage at diagnosis by age

Late stage at diagnosis of bowel cancer in England is more common in younger adults (aged 15-59) in England (61% diagnosed at stage III or IV), compared to older adults (aged 80+) (54% diagnosed at stage III or IV) and those aged 60-79 (53% diagnosed at stage III or IV).[4]

Stage at diagnosis by sex

Late stage at diagnosis of bowel cancer is not associated with sex in England.[4]

These patterns by deprivation, age and sex are probably not explained by other demographic differences.[5]

Stage at diagnosis by ethnicity

Late stage at diagnosis for bowel cancer in England is more common in Black Caribbean patients (54% diagnosed at stage III or IV), compared to White British patients (48% diagnosed at stage III or IV) after adjusting for age, sex and deprivation.[6]

References

  1. National Cancer Registration and Analysis Service. Stage Breakdown by CCG 2014. London: NCIN; 2016.
  2. ISD Scotland, Detect Cancer Early Staging Data. Scotland: ISD; 2016.
  3. Northern Ireland Cancer Registry, Queens University Belfast, Incidence by stage 2010-2014. Belfast: NICR; 2016.
  4. National Cancer Registration and Analysis Service. Routes to diagnosis of cancer by stage 2012-2013 workbook. London: NCRAS; 2016.
  5. Lyratzopoulos G, Abel G, Brown C, et al. Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer. Annals of Oncology, 2012:843-50.
  6. National Cancer Registration and Analysis Service. Ethnicity and stage at diagnosis. London: NCRAS; 2016.

About this data

Data is for: England 2014, Scotland 2014-2015, Northern Ireland 2010-2014, ICD-10 C18-C20 (overall stage at diagnosis) and England, 2012-2013, ICD-10 C18-C20 (stage at diagnosis by deprivation, age, sex, and ethnicity)

Data is not comparable between countries due to differences in time periods and possible differences in how countries record stage at diagnosis.

The proportions of patients diagnosed late only include cases with a known stage at diagnosis and are not adjusted for other demographics differences (e.g. age, sex, ethnicity) unless stated otherwise.

Last reviewed:

The largest proportion of bowel cancer cases occur in the rectum, with slightly smaller proportions in the sigmoid colon Open a glossary item and caecum, and a much smaller proportion in the ascending colon (2010-2012).[1-4]

The proportions of cases in the rectum and sigmoid colon are higher in males (31.5% and 23.1%, respectively) than females (23.1% and 20.4%, respectively). In the caecum and ascending colon, the proportions are higher in females (17.2% and 9.8%, respectively) than males (12.2% and 7.3%, respectively), and there are no marked sex differences in other parts of the bowel.[1-4]

A small proportion of cases did not have the specific part of the colon recorded in cancer registry data, or overlapped more than one part.[1-4]

Cases and percentages may not sum due to rounding

References

  1. Data were provided by the Office for National Statistics on request, July 2014. Similar data can be found here:
    http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/index.html.
  2. Data were provided by ISD Scotland on request, April 2014. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit on request, April 2014. Similar data can be found here:
    http://www.wales.nhs.uk/sites3/page.cfm?orgid=242&pid=59080.
  4. Data were provided by the Northern Ireland Cancer Registry on request, June 2014. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/CancerInformation/.

About this data

Data is for UK, 2010-2012, ICD-10 C18-C20.

Last reviewed:

Bowel cancer incidence rates are projected to fall by 11% in the UK between 2014 and 2035, to 74 cases per 100,000 people by 2035.[1] This includes a larger decrease for males than for females.

For males, bowel cancer European age-standardised (AS) Open a glossary item incidence rates in the UK are projected to fall by 15% between 2014 and 2035, to 87 cases per 100,000 by 2035.[1] For females, rates are projected to fall by 7% between 2014 and 2035, to 63 cases per 100,000 by 2035.[1]

Bowel cancer (C18-C20), Observed and Projected Age-Standardised Incidence Rates, by Sex, UK, 1979-2035

It is projected that 53,646 cases of bowel cancer (29,356 in males, 24,290 in females) will be diagnosed in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C18-C20

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

There is evidence for a small association between bowel cancer incidence and deprivation for males in England, while there is no evidence for an association for females.[1] England-wide data for 2006-2010 show European age-standardised Open a glossary item incidence rates are 13% higher for males living in the most deprived areas compared with the least deprived, while for females the rates are similar for those living in the least and most deprived areas.[1]

Bowel Cancer (C18-C20), European Age-Standardised Incidence Rates by Deprivation Quintile, England, 2006-2010

The estimated deprivation gradient in bowel cancer incidence for males and females living in the most and least deprived areas in England has not changed in the period 1996-2010. It has been estimated that there would have been around 770 fewer bowel cancer cases each year in England during 2006-2010 if all people experienced the same incidence rates as the least deprived.[1]

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.  

About this data

Data is for UK, 2006-2010, ICD-10 C18-C20

Deprivation gradient statistics were calculated using incidence data for 2006-2010. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Age-standardised Open a glossary item rates for White males with bowel cancer range from 54.1 to 55.3 per 100,000. Rates for Asian males are significantly lower, ranging from 19.1 to 28.0 per 100,000 and the rates for Black males are also significantly lower, ranging from 29.7 to 43.8 per 100,000. For females there is a similar pattern - the age-standardised rates for White females range from 34.0 to 34.8 per 100,000, and rates for Asian and Black females are also significantly lower ranging from 11.3 to 17.5 per 100,000 and 20.4 to 31.6 per 100,000 respectively.[1]

Ranges are given because of the analysis methodology used to account for missing and unknown data. For bowel cancer, 146,495 cases were identified; 17% had no known ethnicity.

References

  1. National Cancer Intelligence Network (NCIN) and Cancer Research UK. Cancer Incidence and Survival by Major Ethnic Group, England, 2002-2006. London: NCIN; 2009.

About this data

Data is for UK, 2002-2006, ICD-10 C18-C20.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.